Including PALB2 in the routine molecular genetic testing of breast cancer patients is recommended because it is associated with high cancer risk, and preventive and screening programs in PALB2 carriers may improve their life expectancy similarly to BRCA1/2 carriers. This evidence concerns the gene BRCA1 and breast cancer.